Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.

ABSTRACT: Shigellosis remains a major cause of diarrheal disease in developing countries and causes substantial morbidity and mortality in children. Vaccination represents a promising preventive measure to fight the burden of the disease, but despite enormous efforts, an efficacious vaccine is not available to date. The use of an innovative biosynthetic Escherichia coli glycosylation system substantially simplifies the production of a multivalent conjugate vaccine to prevent shigellosis. This bioconjugation approach has been used to produce the Shigella dysenteriae type O1 conjugate that has been successfully tested in a phase I clinical study in humans. In this report, we describe a similar approach for the production of an additional serotype required for a broadly protective shigellosis vaccine c

SUBMITTER: Ravenscroft N 

PROVIDER: S-EPMC6704370 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature